Cibus advances commercialization of its Clethodim-tolerant HT-3 rice trait through collaborations with Albaugh and RTDC.
Quiver AI Summary
Cibus, Inc. is making significant strides towards commercializing its Clethodim-Tolerant HT-3 rice trait, designed to provide a new weed management solution for U.S. rice farmers. The company has reaffirmed its collaboration with Albaugh and RTDC Corporation to enhance this development, leveraging Albaugh's expertise in crop protection and herbicide registration alongside Cibus' gene editing strengths. This partnership aims to address weed pressure challenges that affect crop yield and quality, with the HT-3 trait expected to be the first of several stacked herbicide-resistant traits offering innovative solutions for rice growers. Cibus is in talks with multiple seed companies to advance this technology, aiming to improve weed management options and ensure high yields in key rice markets globally.
Potential Positives
- Cibus has reaffirmed its collaboration with Albaugh and RTDC, enhancing its market development capabilities for the Clethodim-tolerant HT-3 trait, crucial for successful commercialization.
- The partnership is expected to provide U.S. rice farmers with innovative weed management solutions, addressing critical challenges like weed pressure that affect crop yield and quality.
- Cibus is expanding its strategic partnerships, with four seed partners for the HT-3 trait and ongoing discussions with major rice seed companies in Asia, indicating strong market potential.
- The HT-3 trait represents a significant advancement in herbicide-resistant options for rice growers, positioning Cibus as a leader in the multi-billion-dollar trait industry for agricultural technology.
Potential Negatives
- The press release relies heavily on forward-looking statements, which may create uncertainty for investors regarding the actual outcomes of commercialization efforts.
- There is no confirmed market availability or timeline for the HT-3 trait, potentially leading to skepticism about its viability and the company's prospects.
- Cibus emphasizes its role as a technology company and not a seed company, which may lead to concerns about its ability to effectively market and distribute its traits in a competitive industry.
FAQ
What is Cibus' HT-3 rice trait?
Cibus' HT-3 rice trait is a gene-edited trait that provides herbicide tolerance to help manage weeds in rice crops.
Who are Cibus' partners in the HT-3 initiative?
Cibus partners with Albaugh LLC and RTDC Corporation Limited to enhance the commercialization of the HT-3 rice trait.
How will HT-3 benefit U.S. rice farmers?
The HT-3 trait will provide U.S. rice farmers with improved weed management options, potentially increasing crop yield and quality.
What type of herbicide is associated with HT-3 rice?
The HT-3 rice trait is tolerant to Clethodim, a herbicide that improves weed management for rice farmers.
Is Cibus a seed company?
No, Cibus is a technology company that develops and licenses gene editing traits to seed companies for royalties.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CBUS Insider Trading Activity
$CBUS insiders have traded $CBUS stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $CBUS stock by insiders over the last 6 months:
- GERHARD PRANTE has traded it 17 times. They made 0 purchases and 17 sales, selling 20,700 shares.
- CARLO BROOS (Interim CFO) sold 4,647 shares.
- GREGORY FRANCIS WILLIAM GOCAL (Chief Scientific Officer & EVP) has traded it 3 times. They made 0 purchases and 3 sales, selling 6,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CBUS Hedge Fund Activity
We have seen 35 institutional investors add shares of $CBUS stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 566,328 shares (+16.9%) to their portfolio in Q3 2024
- ARMISTICE CAPITAL, LLC removed 516,000 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 142,849 shares (+inf%) to their portfolio in Q3 2024
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 116,465 shares (-100.0%) from their portfolio in Q2 2024
- STATE STREET CORP added 93,236 shares (+43.6%) to their portfolio in Q3 2024
- NORTHERN TRUST CORP added 89,521 shares (+179.9%) to their portfolio in Q3 2024
- BLACKROCK, INC. added 81,710 shares (+8.3%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Cibus’ Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S.
Cibus and its partners Albaugh and RTDC Continue Their Research and Development Collaboration to Enable Commercialization of Cibus’ Clethodim-Tolerant HT-3 Rice Trait
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) --
Cibus, Inc. (Nasdaq: CBUS),
a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties announced an agreement affirming its collaboration with RTDC Corporation Limited and Albaugh LLC to provide Clethodim as part of Cibus’ weed management solution for U.S. rice farmers using Cibus’ HT-3 trait. This continued collaboration with Albaugh, a global leader in crop protection, lends complementary market development and herbicide registration expertise and experience to Cibus’ gene editing trait expertise. The collaboration is instrumental to Cibus’ herbicide resistant rice trait commercialization efforts as Cibus also continues its work with its U.S. rice seed customers to bring its Clethodim-tolerant trait to market. These seed and crop protection collaborations are expected to bring together the rice production knowledge and expertise needed to successfully deliver improved rice weed management solutions for U.S. rice growers.
Weed pressure impacts crop yield and quality. Herbicide tolerance traits are an important tool for growers to manage weeds and are a key product area of the multi-billion-dollar trait industry globally. Cibus’ Clethodim tolerant HT-3 trait is an important breakthrough for a novel weed management solution for rice farmers and is one of the two herbicide tolerant traits in rice developed by Cibus that are expected to give rice growers excellent new solutions to manage weeds. It expected to be the first of several stacked weed management traits in rice from Cibus. Cibus currently has four seed partners for this trait: two in the United States and two in South America and is in discussion with other major rice seed companies to advance HT-3 rice in Asia.
Chad W. Shelton, Albaugh’s Group Director for Herbicide Tolerant Crops, stated, “This strategic collaboration and innovative technology has a strong potential to help rice growers in the U.S. and strategic rice markets around the globe keep pace with the most up-to-date herbicide-tolerant crop technologies for assuring high yields and crop quality. Albaugh is excited to be a part of this strategic partnership to develop for rice growers a cropping system powered by the HT-3 trait to help create and deliver performance value.”
Calvin Lu, Vice General Manager of RTDC, commented, “This technology combines the best of Gene Editing technologies from Cibus and superior herbicides provided by Albaugh to help rice growers to increase weed management options with better efficacy against difficult weeds. We are proud to be part of this project combining strengths of three companies in terms of technologies and geographies.”
Norm Sissons, Senior Vice President of Seeds and Traits at Cibus, added, “This partnership with Albaugh completes a critical component of our commercial strategy to bring our Clethodim-tolerant HT-3 trait to market. As we further our collaboration with Albaugh and its professional team of experts with a strong commercial focus enabling getting products to market, we see a promising path to bring Cibus’ novel weed management solution to Rice growers.”
About Cibus
Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus is not a seed company. It is a technology company that uses gene editing to develop and license traits to seed companies in exchange for royalties on seed sales. Cibus' long-term focus is productivity traits for farmers for the major global row crops with large acreage such as canola, rice, and soybean. Cibus is a technology leader in high-throughput gene editing technology that is expected to enable it to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Cibus has developed a current pipeline of five productivity traits including important traits for weed management in Rice, Pod Shatter Reduction, and Sclerotinia (disease) resistance, which are its near-term focus.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the offering and the expected use of the proceeds from the offering. Completion of the offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements made by Cibus’ management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
CIBUS CONTACTS:
INVESTOR RELATIONS
Karen Troeber
ktroeber@cibus.com
858-450-2636
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com
MEDIA RELATIONS
Colin Sanford
colin@bioscribe.com
203-918-4347
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
